The Filing Desk

Codexis

CDXS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CDXS · Last close · November 19, 2026
$1.05
Value Codexis yourself

Codexis' revenue rose 18.6% to $70 million in fiscal 2025. Its operating margin was −59.3%, up from −98.6% a year earlier. Free cash flow was −$24 million. The diluted share count rose 18.7%.

Codexis, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 11, 2026 · 0001200375-26-000006 Updated
Revenue
$70M
18.6%
Operating margin
−59.3%
39.3 pts
Net income
−$44M
 
Free cash flow
−$24M
 
Return on capital
−189.5%
21.2 pts
Market cap
$113M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Codexis does

Codexis engineers enzymes, the natural molecules that drive chemical reactions, using its CodeEvolver directed evolution technology. It focuses on improving how complex medicines are made, in two areas: its ECO Synthesis platform for making RNA interference (RNAi) drugs, and its small molecule pharma biocatalysis business.

ECO Synthesis is a set of enzymatic tools and processes meant to allow large-scale manufacture of RNAi therapeutics, drugs that silence certain genes. In its small molecule business, it develops enzymes that some of the world's largest pharmaceutical companies use to make their manufacturing more efficient.

It says it is testing the feasibility of its process with several partners and expects to advance at least one of them in 2026.

Its biggest risks, as it describes them

  • A history of net losses, with no assurance it will become or stay profitable.
  • Reliance on a limited number of customers.
  • Supply agreements with customers that may not be renewed and need not commit them to buy.
  • Regulators may disagree that its products are exempt from drug manufacturing rules.
  • Problems or higher costs at its facilities, or in providing complex services.
From Codexis's annual report on Form 10-K, filed March 11, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Codexis lost money in fiscal 2025: a net loss of $44 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments117114657478
Debt incl. finance leases——02940
Net debt (negative means net cash)——−65−45−38
Net debt to EBITDA—————
Debt to equity——0.0x0.4x0.8x
Interest coverage−1,621.2x−1,025.9x−1,547.0x−22.8x−13.2x
Current ratio4.8x3.3x2.6x4.2x3.8x
Quick ratio4.8x3.3x2.5x4.1x3.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Codexis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Codexis says to expect

  • Full year 2026: total revenuesTotal revenues are expected to be in the range of $72 million to $76 million.
  • Full year 2026: gross marginGross margin for the year 2026 is expected to be in the low 70% range.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Codexis shares on the open market, and 5 insiders sold $933,396.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 16, 2026Alison MoorePresident and CEO, DirectorSold10,651$1.14$12,111Form 4
Jun 11, 2026Vre Raymond DeDirectorSold2,605$2.37$6,174Form 4
Feb 24, 2026Stefan LutzChief Scientific OfficerSold5,862$1.13$6,624Form 4
Feb 6, 2026Alison MoorePresident and CEO, DirectorSold3,826$1.31$5,012Form 4
Feb 6, 2026Stefan LutzChief Scientific OfficerSold2,492$1.31$3,265Form 4
Jan 7, 2026Stefan LutzCSOSold4,685$1.70$7,964Form 4
Dec 1, 2025Opaleye Management Inc.10% ownerSold253,533$1.67$423,400Form 4
Nov 28, 2025Opaleye Management Inc.10% ownerSold107,490$1.75$188,108Form 4
Nov 26, 2025Opaleye Management Inc.10% ownerSold153,318$1.74$266,773Form 4
Nov 21, 2025Dennis P WolfDirectorSold8,952$1.56$13,965Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—3 of 94 of 9
Rule of 40−130.7%−105.9%−15.3%
Altman Z''−10.64−10.79−11.56
Accruals ratio−12.2%−11.1%−16.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets—FailFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsFailPassPass
F-score—3 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Codexis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CodexisFY2518.6%−59.3%−33.9%−189.5%—4
PersonalisFY25−17.7%−126.4%−114.1%———Compare
Standard BiotoolsFY25−6.2%−129.2%−96.8%−41.9%—4Compare
Harvard BioscienceFY25−8.1%−56.1%6.3%−56.0%—3Compare
Alpha TeknovaFY257.3%−41.9%−24.2%−22.0%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue4950616869105139705970
Revenue growth16.8%2.4%21.1%13.0%0.9%51.7%32.3%−49.4%−15.4%18.6%
Gross profit393648535582101574361
Research and development22303034445680594652
Operating income−9−23−11−12−24−23−35−68−58−42
Net income−9−23−11−12−24−21−34−76−65−44
Diluted EPS (US$)−0.21−0.50−0.21−0.21−0.40−0.33−0.51−1.12−0.89−0.50
Diluted shares (millions)41465256596565687387
Cash flow
Cash from operations−2−9−14−13−16−1411−53−49−19
Capital expenditure11344148444
Free cash flow−3−10−17−16−20−283−57−54−24
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation678781214101310
Balance sheet at fiscal year end
Cash and short-term investments12313290149117114657478
Debt incl. finance leases00—————02940
Total assets365479149222246250137149148
Total liabilities162923445282106508297
Shareholders' equity192456106170164145876750
Margins and ratios
Gross margin80.0%71.4%79.2%77.2%80.1%78.8%72.6%81.7%72.5%86.7%
Operating margin−17.5%−45.9%−18.6%−18.3%−34.6%−21.7%−25.2%−97.0%−98.6%−59.3%
Net margin−17.5%−46.0%−17.9%−17.4%−34.8%−20.3%−24.2%−108.7%−110.0%−62.5%
Free cash flow margin−5.6%−19.5%−27.8%−23.8%−29.3%−26.8%2.1%−81.3%−90.5%−33.9%
Rule of 40 (growth + FCF margin)11.2%−17.0%−6.7%−10.8%−28.4%24.9%34.5%−130.7%−105.9%−15.3%
Return on capital————————−210.7%−189.5%
Return on equity−40.8%−105.4%−26.9%−14.8%−17.4%−12.7%−21.7%−65.9%−85.0%−74.9%
Return on assets−21.3%−51.5%−16.4%−10.4%−12.9%−9.1%−13.5%−39.4%−45.7%−29.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Codexis' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Codexis.